{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:01:50Z","timestamp":1785765710543,"version":"3.56.0"},"reference-count":31,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Anti-obesity medications (AOMs), led by the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide and the dual GIP\/GLP-1 receptor agonist tirzepatide, have produced substantial weight reduction and growing signals of benefit that extend well beyond adiposity. These agents are now discussed in relation to longevity and aesthetic medicine, raising the question of whether their effects reach ageing biology and appearance. This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, and Clinical trial registries; January 2010\u2013June 2026) integrates mechanistic studies, randomised cardiovascular and renal outcome trials, ageing-biomarker analyses, body-composition data, and patient-facing aesthetic phenomena. The evidence indicates that AOMs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations; exploratory proteomic and epigenetic analyses further suggest effects partly independent of weight loss, though these do not establish slowed ageing. Newer multi-receptor agents act with greater metabolic specificity: glucagon-containing agents such as survodutide and the triple agonist retatrutide preferentially reduce visceral and hepatic fat (liver-fat reductions of roughly 60\u201380% in places), a quality of weight loss arguably more relevant to healthspan than its quantity. Concurrently, rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed \u201cOzempic face\u201d and \u201cOzempic body\u201d, alongside accelerated skin laxity and loss of lean mass, the latter tempered by data showing lean-loss proportions comparable to established agents.<\/jats:p>","DOI":"10.3390\/jcm15156026","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"6026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Obesity Medications in Longevity and Aesthetic Medicine"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-0865","authenticated-orcid":false,"given":"Julia","family":"Bijoch","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","unstructured":"World Obesity Federation (2024). World Obesity Atlas 2024, World Obesity Federation. Available online: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2024."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Jastreboff, A.M. (2026, January 5\u20138). Results of the First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in Patients with Obesity (TRIUMPH-1). Proceedings of the 86th Scientific Sessions of the American Diabetes Association, New Orleans, LA, USA."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/s41591-026-04397-4","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update","volume":"32","author":"Ciudin","year":"2026","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"ref_9","unstructured":"American Society of Plastic Surgeons (2025). 2024 ASPS Procedural Statistics Report, American Society of Plastic Surgeons. Available online: https:\/\/www.plasticsurgery.org\/plastic-surgery-statistics."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105836","DOI":"10.1016\/j.ebiom.2025.105836","article-title":"Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3","volume":"118","author":"Carvas","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: An expanding universe","volume":"186","author":"Blasco","year":"2023","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.cell.2023.08.003","article-title":"Biomarkers of aging for the identification and evaluation of longevity interventions","volume":"186","author":"Moqri","year":"2023","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1038\/s41467-026-72861-3","article-title":"Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy","volume":"17","author":"Corley","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1126\/science.1172539","article-title":"Extending healthy life span\u2014From yeast to humans","volume":"328","author":"Fontana","year":"2010","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"le Roux, C.W., Wharton, S., Startseva, E., Kloer, I.M., Hussain, S.A., Unseld, A., Bozkurt, B., Ard, J.D., Bays, H.E., and Bogda\u0144ski, P. (2026). Survodutide once weekly for the treatment of adults with obesity. N. Engl. J. Med., Epub ahead of printing.","DOI":"10.1056\/NEJMoa2600751"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kaplan, L.M., Startseva, E., le Roux, C.W., Wharton, S., Bozkurt, B., Mazo, D.F., von Schlippenbach, J., Gonz\u00e1lez Maldonado, S., Ajaz Hussain, S., and Neff, G.W. (2026). Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med., Epub ahead of printing.","DOI":"10.1038\/s41591-026-04479-3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone-receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: A substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:19:27Z","timestamp":1785763167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":31,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156026"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156026","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}